A global pandemic fiasco sets the stage for Tillman Gerngross to introduce his biotech unicorn to Wall Street
This morning we got a better look at the numbers Tillman Gerngross has in mind for his pandemic play at Adagio Therapeutics. And not surprisingly, they are big.
Gerngross has had plenty of experience judging value in biotech. And at a time the top mRNA players at Moderna and BioNTech/Pfizer are reaping some vast gains from their truly revolutionary new vaccines for Covid-19, it’s clear that the Dartmouth professor has been building a unicorn of his own.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.